Neurogastrx is a pharmaceutical company developing products to treat gastrointestinal disorders, focusing on diseases where patients have clear unmet needs and leveraging our expertise in neurogastroenterology.
Neurogastrx's lead product, NG101, is a peripherally restricted, selective and potent dopamine D2/D3 receptor antagonist. Neurogastrx has generated data showing the potential value of NG101 in treating chronic nausea such as gastroparesis. Chronic nausea and vomiting is a condition greatly affecting the life of millions of patients in the US alone. Currently approved treatments, although effective, have side effects potentially debilitating, or life-threatening.
The pipeline also includes NG202 for Irritable Bowel Syndrome with Diarrhea (IBS-D) and NG301 for constipation associated with Parkinson's disease.